Invizyne (EXOZ) - Koefisien utang jangka dawa marang modal

Invizyne - logo grafis emiten EXOZ

The eXoZymes Inc (EXOZ) chart on the GURU.Markets platform reflects the dynamics of a company establishing biochemical capacities through partnerships with plants, where the indicator stands at 0.18. A lack of profitability and a reliance on investment make the enzyme development stage extremely risky. The business relies on outsourcing production and cloud computing for AI training, functioning as an advanced research center.

Invizyne Technologies (EXOZ): Utang jangka dawa marang ekuitas saka 13.02.2025 nganti 30.10.2026
Produk mawa merek eXoZymes Inc

To minimize fundamental risks, investors evaluate the long-term debt-to-equity ratio, which determines the degree of financial leverage and the company's reliance on external borrowings with maturities exceeding one year. Analyzing the long-term debt-to-equity structure reveals the extent to which the scaling of biochemical developments at eXoZymes Inc. (EXOZ) relies on borrowed funds versus internal resources during the expansion of green chemistry.

Analisis perusahaan pesaing

Haleon PLC - Kewajiban jangka dawa marang ekuitas|Utang jangka dawa marang modal KVUE|VRNA (Verona Pharma Inc.) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal MENS (Jyong Biotech Ltd)|Utang jangka dawa marang modal ligand.com LGND|AMRX - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal PRGO (Perrigo Company PLC)|Alvotech Corp (ALVO) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas Liquidia Inc.|GLPG (Galapagos NV) - Utang jangka dawa marang modal|Utang jangka dawa marang modal anipharmaceuticals.com|Rasio utang jangka dawa marang ekuitas MNKD (MannKind)|AMPH (Amphastar Pharmaceuticals Inc) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Pacira PCRX|ARS Corp (SPRY) - Kewajiban jangka dawa marang modal|TBPH: Rasio utang jangka dawa marang ekuitas|aquestive.com - Rasio silihan jangka dawa marang modal|SCPH: Utang jangka dawa marang modal|Tectonic Therapeutic - Koefisien utang jangka dawa marang modal|TNXP (Tonix Pharmaceuticals Inc.) - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal SXT China SXTC|Utang jangka dawa marang ekuitas Eupraxia Pharmaceuticals (EPRX)|BHST (bioharvest.com) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal ORMP (Oramed Pharmaceuticals Inc.)|Entera Bio Ltd (ENTX) - Kewajiban jangka dawa marang modal|HYFT: Rasio utang jangka dawa marang ekuitas|ABVC (ABVC BioPharma, Inc) - Rasio utang jangka dawa marang modal|Cumberland Pharmaceuticals (CPIX) - Utang jangka dawa marang ekuitas|Kewajiban jangka dawa marang modal quantumbiopharma.com (QNTM)|Rasio utang jangka dawa marang ekuitas FGEN|Telomir Pharmaceuticals Inc - Kewajiban jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas RANI (Rani Therapeutics)|SNYR - Kewajiban jangka dawa marang modal|Utang jangka dawa marang ekuitas Rallybio RLYB|LEXX - Rasio utang jangka dawa marang ekuitas|Pulmatrix - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Pheton Holdings Ltd|aptorumgroup.com (APM) - Utang jangka dawa marang ekuitas|LYRA - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas IBO|TNFA: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal YCBD|Rasio tanggungan utang jangka dawa marang modal PainReform Ltd|Utang jangka dawa marang ekuitas Altamira Therapeutics Ltd. CYTO|LIPO: Rasio utang jangka dawa marang modal|OptiNose, Inc. - Utang jangka dawa marang modal|pieris.com (PIRS) - Rasio utang jangka dawa marang ekuitas|PROC: Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Petros Pharmaceuticals Inc (PTPI)|Rasio utang jangka dawa marang ekuitas QLI|Rasio utang jangka dawa marang modal SLRN (ACELYRIN Inc.)|Utang jangka dawa marang ekuitas TFF Pharmaceuticals (TFFP)